Project Grant HT94252410148

The Defense Health Agency awarded a $458,516 Project Grant to Mayo Clinic Jacksonville to support research titled "NOVEL THERAPEUTICS TARGETING STRESS GRANULES FOR C9ORF72-MEDIATED ALS." The grant period runs from February 1, 2021 through June 30, 2022. The grant supports research into novel therapeutics targeting stress granules for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the C9orf72 gene. This work falls under the Military Medical Research and...

This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....

The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...

This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop neuronal exosome-based biomarkers for the diagnosis and disease progression of amyotrophic lateral sclerosis (ALS). The total award amount is $1,181,251.00, with a performance period from April 15, 2025 to April 14, 2028. The principal investigator for this grant is the University of California, Los Angeles (UCLA), which has a...

The University of California, San Diego (UCSD) was awarded a $2,179,391 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct proof-of-concept preclinical studies and GMP development of AAV-SynCav1 gene technology to treat amyotrophic lateral sclerosis (ALS). The award, which began on May 1, 2024, will support research and development efforts aimed at advancing a novel gene therapy approach to address this debilitating...

This Project Grant award of $925,757.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Wake Forest University Health Sciences (WFUHS) for the project "SELECTIVE REDUCTION OF REPEAT EXPANSION RNA WITH SMALL MOLECULES TO TREAT C9ORF72 MEDIATED ALS." The funding supports advanced biomedical research to develop innovative medical solutions that address critical health challenges relevant to military personnel and...

The U.S. Defense Health Agency awarded a $1,979,313 Project Grant to Sachi Bioworks, Inc., a small disadvantaged business in Erie, Colorado, to develop a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). This award is part of the agency's Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. Sachi Bioworks specializes...